Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Management of Hypoxic Ischemic Encephalopathy in Neonates
NCT07305350Phase 2Active, not recruiting
- Sponsor
- University of Child Health Sciences and Children's Hospital, Lahore
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of melatonin in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University of Child Health Sciences and Children's Hospital, Lahore. Primary endpoint: Neonate survival rate at 28 days. Started Dec 2025; status: active, not recruiting.
02
Drugs
melatonin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT07305350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305350.